Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.

[1]  J. Griggs,et al.  Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Vaidya,et al.  Erratum: Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial (Lancet (2014) 383 (603-613)) , 2014 .

[3]  L. Esserman,et al.  Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial , 2014, The Lancet.

[4]  C. Coles,et al.  Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Luini,et al.  Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. , 2013, The Lancet. Oncology.

[6]  Joanne S Haviland,et al.  The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. , 2013, The Lancet. Oncology.

[7]  G. Papadatos,et al.  The impact of breast cosmetic and functional outcomes on quality of life: long-term results from the St. George and Wollongong randomized breast boost trial , 2013, Breast Cancer Research and Treatment.

[8]  H. Putter,et al.  Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC 'boost versus no boost' trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  H. Bartelink,et al.  Has partial breast irradiation by IORT or brachytherapy been prematurely introduced into the clinic? , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  D. Verellen,et al.  Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial , 2012, Radiation oncology.

[11]  Gustavo Werutsky,et al.  Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. , 2012, The Lancet. Oncology.

[12]  Y. Chin,et al.  Radiotherapy breast boost with reduced whole-breast dose is associated with improved cosmesis: the results of a comprehensive assessment from the St. George and Wollongong randomized breast boost trial. , 2012, International journal of radiation oncology, biology, physics.

[13]  Emmanuel Barillot,et al.  Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women , 2012, Clinical Cancer Research.

[14]  Early Breast Canc Trialists Collab.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials , 2011 .

[15]  R Peto,et al.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials , 2011, The Lancet.

[16]  H. Bartelink,et al.  Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  G. Nieuwenhuijzen,et al.  Localization of non‐palpable breast cancer using a radiolabelled titanium seed , 2010, The British journal of surgery.

[18]  A. Hart,et al.  Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. van Limbergen,et al.  Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Michel Bolla,et al.  Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. , 2008, European journal of cancer.

[21]  Laurence Collette,et al.  Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial , 2007 .

[22]  A. Vincent-Salomon,et al.  Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  Steven Eschrich,et al.  Prediction of radiation sensitivity using a gene expression classifier. , 2005, Cancer research.

[24]  L Collette,et al.  Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? , 2003, European journal of cancer.

[25]  G. Németh,et al.  Electron and High-Dose-Rate Brachytherapy Boost in the Conservative Treatment of Stage I–II Breast Cancer , 2002, Strahlentherapie und Onkologie.

[26]  I. Barillot,et al.  Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. , 2001, The New England journal of medicine.

[27]  L Collette,et al.  The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[29]  M. J. van de Vijver,et al.  Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. , 1998, International journal of radiation oncology, biology, physics.

[30]  P. Romestaing,et al.  Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Arriagada,et al.  Conservative management of breast cancer , 1986, The British journal of surgery.

[32]  B Fisher,et al.  Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. , 1985, The New England journal of medicine.

[33]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[34]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.